Export
Model List of Essential Medicines
clear
Found 246 recommendations for 77 medicines and 18 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
-
Abiraterone General information
SectionHormones and antihormones- Oral > Solid: 250 mg; 500 mg
Indications -
Afatinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
All-trans retinoic acid General information
SectionTargeted therapies- Oral > Solid: 10 mg capsule
-
Allopurinol General information
SectionSupportive medicines- Oral > Solid: 100 mg; 300 mg
Indications -
Anastrozole General information
SectionHormones and antihormones- Oral > Solid: 1 mg tablet
-
Arsenic trioxide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
-
Asparaginase General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
Indications -
Bendamustine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
-
Bicalutamide General information
SectionHormones and antihormones- Oral > Solid: 50 mg
Indications -
Bleomycin General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
-
Bortezomib General information
SectionTargeted therapies- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
Indications -
Calcium folinate General information
SectionCytotoxic medicines- Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
-
Capecitabine General information
SectionCytotoxic medicines- Oral > Solid: 150 mg tablet; 500 mg tablet
-
Carboplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
IndicationsOther specified gliomas of brain Osteosarcoma of bone and articular cartilage of unspecified sites Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis -
Chlorambucil General information
SectionCytotoxic medicines- Oral > Solid: 2 mg tablet
-
Cisplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
IndicationsOther specified gliomas of brain Malignant neoplasms of nasopharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx -
Cyclophosphamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid: 25 mg tablet; 50 mg tablet
IndicationsOther specified gliomas of brain Malignant neoplasms of kidney, except renal pelvis Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified malignant neoplasms of breast Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Rhabdomyosarcoma primary site Hodgkin lymphoma -
Cytarabine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
-
Dacarbazine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection
Indications -
Dactinomycin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 µg in vial powder for injection
-
Dasatinib General information
SectionTargeted therapies- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
-
Daunorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
-
Dexamethasone General information
SectionHormones and antihormones- Oral > Solid: 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
-
Docetaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
-
Doxorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
IndicationsMalignant neoplasms of breast Other specified malignant neoplasms of breast Hodgkin lymphoma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Kaposi sarcoma of unspecified primary site Diffuse large B-cell lymphomas -
Enzalutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to abiraterone for Malignant neoplasms of prostate -
Erlotinib General information
SectionTargeted therapies- Oral > Solid: 100 mg; 150 mg
-
Etoposide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule; 50 mg capsule
IndicationsOther specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Hodgkin lymphoma Other specified malignant neoplasms of the ovary Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Retinoblastoma Myeloid leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites -
Everolimus General information
SectionTargeted therapies- Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)
Indications -
Filgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
Indications -
Fludarabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)
-
Fluorouracil General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
-
Flutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide for Malignant neoplasms of prostate -
Gefitinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
Gemcitabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
-
Goserelin General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate -
Hydrocortisone General information
SectionHormones and antihormones- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
-
Hydroxycarbamide General information
SectionCytotoxic medicines- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
-
Ibrutinib General information
SectionTargeted therapies- Oral > Solid: 140 mg
-
Ifosfamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
IndicationsOther specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis -
Imatinib General information
SectionTargeted therapies- Oral > Solid: 100 mg; 400 mg
-
Irinotecan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
-
Lenalidomide General information
SectionImmunomodulators- Oral > Solid: 25 mg
Indications -
Leuprorelin General information
SectionHormones and antihormones- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
-
Melphalan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg
Indications -
Mercaptopurine General information
SectionCytotoxic medicines- Oral > Solid: 50 mg tablet
-
Mesna General information
SectionSupportive medicines- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
IndicationsOsteosarcoma of bone and articular cartilage of other specified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis -
Methotrexate General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
Indications -
Methylprednisolone General information
SectionHormones and antihormones- Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
-
Nilotinib General information
SectionTargeted therapies- Oral > Solid: 150 mg capsule; 200 mg capsule
-
Nilutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide for Malignant neoplasms of prostate -
Nivolumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
Indications -
Oxaliplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
-
Paclitaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 6 mg per mL
IndicationsOther specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri -
Pegaspargase General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 3750 units per 5 mL in vial
Indications -
Pembrolizumab General information
SectionImmunomodulatorsIndicationsTherapeutic equivalent to nivolumab for Melanoma of skin -
Prednisolone General information
SectionHormones and antihormones- Oral > Solid: 5 mg; 25 mg
- Oral > Liquid: 5 mg per mL
-
Prednisone General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Follicular lymphoma Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Burkitt lymphoma including Burkitt leukaemia Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate -
Procarbazine General information
SectionCytotoxic medicines- Oral > Solid: 50 mg (as hydrochloride)
Indications -
Rasburicase General information
SectionSupportive medicines- Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution
Indications -
Realgar-indigo naturalis formulation General information
SectionCytotoxic medicines- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
-
Rituximab General information
SectionTargeted therapies- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
-
Tamoxifen General information
SectionHormones and antihormones- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
-
Thalidomide General information
SectionImmunomodulators- Oral > Solid: 50 mg
Indications -
Tioguanine General information
SectionCytotoxic medicines- Oral > Solid: 40 mg
Indications -
Trastuzumab General information
SectionTargeted therapies- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
Indications -
Triptorelin General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate -
Vinblastine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
-
Vincristine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
IndicationsOther specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Retinoblastoma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Kaposi sarcoma of unspecified primary site -
Vinorelbine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
- Oral > Solid: 20 mg; 30 mg; 80 mg
-
Zoledronic acid General information
SectionSupportive medicines- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle